ClinicalTrials.gg
Active, not recruitingNCT06480500Ket-CBTUpdated Oct 6, 2026

i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

A Phase 2 interventional study of Ketamine hydrochloride and i-CBT (Internet-based Cognitive Behavioural Therapy) in Major Depressive Disorder, Suicide and Treatment Resistant Depression, sponsored by University Health Network, Toronto. Active, not recruiting at 1 site in Canada. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Planned enrollment
22nd of 89
76 · median 38
Started
2024
with 7 others
Phase 2
22 of 89
7 open now
Primary completion
2027-03
later than 11 of 25 live
Registered
67th of 89
by date

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 22nd largest by planned enrollment, is one of 8 that started in 2024, is one of 22 in phase 2, reaches primary completion later than 11 of the 25 other live ones, and was the 67th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years). Most people with depression experience thoughts of suicide and many will also plan and/or attempt suicide at some time in their life. There is an urgent need for new scalable treatments that can effectively reduce suicidality in people with depression.

Cognitive behavioural therapy (CBT) reduces suicidal thoughts and behaviours, and can be delivered through the internet (i-CBT) making it more accessible and scalable. However, i-CBT has not been shown to rapidly reduce suicidal thoughts and behaviours (suicidality), such as within 24 hours. IV ketamine on the other hand has been shown to rapidly reduce thoughts of suicide, but not suicidal behaviours.

Therefore, combining i-CBT with IV ketamine may be more effective reducing suicidality than i-CBT treatment with a control treatment.

The investigators propose a 13-week, multi-site, study that looks at how combining i-CBT and IV ketamine treatment will affect suicidality in individuals with depression who have recently experienced suicidal thoughts and/or behaviours, but have not responded to previous treatment. All 76 participants will receive a weekly session of i-CBT for 13 weeks, but half will be randomly assigned to also receive six IV ketamine treatments or six IV midazolam treatments (control treatment) over the first initial 30 days. The investigators will measure changes in suicidal thoughts and behaviours before drug treatment and at the primary endpoint (i.e.,day 30), and after 3 months (i.e. Day 91) of the starting treatment.

03

Conditions studied

  • Major Depressive Disorder
  • Suicide
  • Treatment Resistant Depression

Keywords

  • MDD
  • Ketamine
  • Internet-Based Cognitive Behavioural Therapy
  • Suicide
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written, voluntary prior to study enrollment. Substitute decision makers will not be allowed to consent to study on a potential patient's behalf.
  2. Male or female between the age of 21 to 65, inclusive.
  3. Meets criteria for Major Depressive Disorder, currently experiencing a Major Depressive Episode (MDE) without psychotic features. Diagnosis will be confirmed using the Mini-International Neuropsychiatric Interview (MINI) conducted by a delegated physician or trained research study staff.
  4. Must present with a moderate to severe depressive episode, as determined by the MADRS score greater than 21.
  5. Must be at risk for suicide, operationalized as a response of 'yes' to items 1 or 2 on the Suicidal Ideation subscale or 'yes to any item of the Suicidal Behaviour subscale on the C-SSRS.
  6. Current MDE has inadequate response to two or more adequate treatment trials for MDD, as per the 2016 CANMAT Depression Guidelines.
  7. Access to reliable internet for the entire study period and an internet-based device (i.e., a smartphone, laptop, desktop or tablet).
  8. Must have the ability to speak and read English. This is due to the i-CBT modules only being offered in English presently.

Exclusion criteria

Exclusion Criteria:

  1. Currently has symptoms of mania or hypomania or mixed state bipolar, as determined by the Young Mania Rating Scale (YMRS) score greater than 12.
  2. Current symptoms of psychosis or a substance use disorder within the past 3 months. Past history of psychotic features during a mood episode will not be excluded. Other secondary psychiatric comorbidities (e.g. anxiety disorders, trauma related disorders, etc.) will not be excluded.
  3. Lifetime history of a primary psychotic disorder (including, but not limited to, schizophrenia or schizoaffective disorder).
  4. Lifetime history of ketamine use disorder.
  5. History of neurological disorders (including, but not limited to, uncontrolled seizure disorder, history of stroke within past 12 months, major head injuries, aneurysmal vascular disease [including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels], arteriovenous malformation, or intracerebral hemorrhage).
  6. Presence a relative or absolute to ketamine or midazolam, including a drug allergy, stroke history, uncontrolled hypertension, low or labile blood pressure (as defined by a baseline systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg), recent myocardial infarction within past 12 months, cardiac arrhythmia, severe coronary artery disease, heart failure or moderate to severe hepatic impairment (defined as a score of B or C) or severe renal impairment ( (GFR) \< 45 milliliters/min).
  7. Pregnant or breastfeeding women or women who intend to get pregnant. Patients who are sexually active must agree to use a highly effective method.
  8. Use of prohibited concomitant medications, which includes other forms of ketamine including racemic ketamine and esketamine, benzodiazepines, monoamine oxidase inhibitors, stimulants or medical cannabis of any form. All other medications will be permitted.
  9. Currently receiving CBT or CBT-related interventions (e.g., Dialectical Behavioural Therapy).
  10. Changes in medication or non-CBT psychotherapy one month prior to study enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    i-CBT and IV ketamine

    Participants will receive internet-based cognitive therapy (i-CBT) for 13 weeks. During the first 4 weeks of i-CBT, participants will also be administered 6 infusions of ketamine intravenously. The first two infusions will be dosed at 0.5 mg/kg over a period of 40 mins. For infusions 3 and 4, patients will be flexibly-dosed between 0.5 mg/kg to 0.75 mg/kg, depending on clinical response to first two infusions. For infusions 5 and 6, patients will be flexibly-dosed between 0.5-0.85 mg/kg, depending on the clinical response to the first 4 infusions.

    Drug: Ketamine hydrochloride · Behavioral: i-CBT (Internet-based Cognitive Behavioural Therapy)

  • Active comparator
    i-CBT and IV midazolam

    Participants will receive internet-based cognitive therapy (i-CBT) for 13 weeks. During the first 4 weeks of i-CBT, participants will also be administered 6 infusions of midazolam intravenously. The first two infusions will be dosed at 0.02 mg/kg over a period of 40 mins. For infusions 3 and 4, patients will be flexibly-dosed between 0.02 mg/kg to 0.03 mg/kg, depending on clinical response to first two infusions. For infusions 5 and 6, patients will be flexibly-dosed between 0.02 mg/kg to 0.035 mg/kg, depending on the clinical response to the first 4 infusions.

    Behavioral: i-CBT (Internet-based Cognitive Behavioural Therapy) · Drug: Midazolam Hydrochloride

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    38 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.

  • Behaviorali-CBT (Internet-based Cognitive Behavioural Therapy)

    Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.

  • DrugMidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    38 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.

06

What researchers measure

Primary outcomes

  1. Suicidality severity using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The CSSRS evaluates suicidal ideation and behaviour. The CSSRS evaluates suicidal ideation and behaviour. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

    Time frame: 30 Days, up to 91 Days.

Secondary outcomes

  1. Objective Depressive Symptom Severity using the Montgomery-Asberg Depression Rating Scale (MADRS)

    The MADRS is a scale measuring objective depression severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60; higher scores denote greater severity.

    Time frame: Day 30, Day 91

  2. Subjective Depressive Symptom Severity using the McIntyre and Rosenblat Rapid Response Scale (MARRRS)

    The MARRRS is a self-reported 14-item self-report measure of depressive symptoms present during the past 72 hours. Total score ranges from 0 to 42; a higher score indicates greater symptom severity.

    Time frame: Day 30, Day 91

  3. Subjective Depressive Symptom Severity using Quick Inventory for Depressive Symptomatology, Self-Report, 16-item (QIDS-SR-16)

    The QIDS-SR-16 total score ranges from 0 to 27 with 0 representing no depression and 27 representing severe depression.

    Time frame: Day 30, Day 91

  4. Symptom Severity and Treatment response using the Clinical Global Impressions Scale (CGI)

    The CGI severity module assesses the severity of a person's depressive illness using a seven-point Likert scale, ranging from "Normal, not at all depressed" to "Among the most extremely depressed patients". The CGI improvement module evaluates the global improvement of a person's condition since their last visit on a seven-point Likert scale, ranging from "Very much improved" to "Very much worse".

    Time frame: Day 30, Day 91

  5. Dissociative Symptom Severity using the Clinician-Administered Dissociative States Scale (CADSS), 23-item

    The CADSS measures objective dissociative symptom severity post infusion. Total scores on the 23-item CADSS range from 0 to 92; a higher score denotes greater dissociative symptom severity.

    Time frame: 30 minutes Post-Infusion

  6. Treatment-Emergent Psychiatric Symptoms using the Brief Psychiatric Rating Scale (BPRS)

    The BPRS rating scale has 18 items, each item rated on a severity scale of 1 (not present) to 7 (extremely severe). 0 is entered if the item is not assessed.

    Time frame: 30 minutes Post infusion, Day 30, Day 91

  7. Treatment-Emergent Manic Symptoms using the Young Mania Rating Scale (YMRS)

    The Young Mania Rating Scale (YMRS) is a clinical interview scale to assess the severity of manic states and in this study to look at treatment-emergent mania. Total scores range from 0 to 60, with higher scores indicative of greater symptom severity.

    Time frame: 30 minutes Post infusion, Day 30, Day 91

  8. Mystical Type Experiences using the Mystical Experiences Questionnaire (MEQ)

    The MEQ consists of 30 items, each item rated on a Likert scale (0-None/not at all to 5-Extreme, more than any other time in my life). The MEQ total score is computed by taking the average response to all items.

    Time frame: 30 minutes Post Infusion, Day 30, Day 91

  9. Subjective Wellbeing using the World Health Organization-5 Well-Being Index (WHO-5)

    The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life.

    Time frame: Day 30, Day 91

  10. Impairments in Work and Activities using the World Productivity and Impairment Questionnaire (WPAI)

    The WPAI is a six-item self-administered rating scale measuring work absenteeism, presenteeism, and productivity loss and daily activity impairment. Individuals are asked to rate to what extent health problems affected their ability to do regular daily activities other than work at a job (0-No effect on daily activities to 10-Completely prevented me from doing my daily activities). Respondents who are currently employed are additionally asked to rate the number of hours missed from work due to health problems, the number of hours missed due to other reasons (e.g., vacation, time off to participate in this study), and the number of hours worked in the past seven days, as well as to what extent health problems affected productivity while working (0-No effect on my work to 10-Completely prevented me from working). Responses to each question are scaled to an overall percentage score (0 to 100), with higher values denoting greater impairment

    Time frame: Day 30, Day 91

  11. Subjective Cognitive Impairment using the Perceived Deficits Questionnaire - Depression - 5-Item (PDQ-5-D)

    The PDQ-5-D total scores range from 0 to 20, with greater scores indicative of greater subjective cognitive impairment.

    Time frame: Day 30, Day 91

  12. Cognitive Function using the Digit Symbol Substitution Test (DSST)

    The DSST assesses relative contributions of speed, memory, executive function and visual scanning. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within 90 seconds for a total possible score of 0 to 90. A higher score reflects greater performance.

    Time frame: Day 30, Day 91

  13. Cognitive Processing Speed using the Trail Making Test A (TMT-A)

    The TMT is a two-part cognitive test. TMT-A assesses cognitive processing speed and consists of 25 circles distributed over a sheet of paper. Participants are asked to connect circles in numerical sequence. If a participant makes a mistake, the administrator points out the error, and the participant must return to the last correct circle and continue the task. Lower scores represent better performance.

    Time frame: Day 30, Day 91

  14. Executing Functioning using the Trail Making Test B (TMT-B)

    The TMT is a two-part cognitive test. TMT-B assesses executive functioning and consists of 25 circles distributed over a sheet of paper. Participants are asked to connect circles in alternating numerical and alphabetical sequence (e.g., 1-A-2-B). If a participant makes a mistake, the administrator points out the error, and the participant must return to the last correct circle and continue the task. Lower scores represent better performance.

    Time frame: Day 30, Day 91

  15. Anxiety using the Generalized Anxiety Disorder-7 (GAD-7)

    Total score ranges from 0 to 21; a higher score denotes greater symptom severity.

    Time frame: Day 30, Day 91

  16. Hedonic/Pleasure Capacity using the Snaith-Hamilton Pleasure Scale (SHAPS)

    The SHAPS total score ranges from 14 to 56, wherein a higher score indicates greater hedonic capacity (lower anhedonic severity).

    Time frame: Day 30, Day 91

  17. Reaction Time using the Choice Reaction Time Identification Task (CRT)

    For the CRT, 4 boxes are presented on the screen in a horizontal array. Each box has an assigned response key (by default, the response keys are matched spatially to the position of their assigned boxes: DFJK). After a fixed amount of time, one of the boxes turns red and participants are asked to press the corresponding response key as fast as possible. The response time for correct responses is recorded, with larger numbers representing slower reaction time.

    Time frame: Day 30, Day 91

  18. Psychomotor signs of depression using the Core Assessment of Psychomotor Change (CORE)

    The CORE is an observer-rated instrument evaluating cognitive processing disorders (non-interactiveness), agitation, and motor retardation. Scores range from 0 to 54, with higher scores representing more psychomotor signs of depression.

    Time frame: Day 30, Day 91

  19. Verbal Fluency using the FAS test

    The F-A-S Test assesses phonemic verbal fluency by requesting an individual to orally produce words that begin with the letters F, A and S. High scores indicate better phonemic verbal fluency.

    Time frame: Day 30, Day 91

  20. Verbal Memory using the California Verbal Learning Test Second Edition (CVLT-II)

    In the CVLT-II, a participant listens to series of words and is then asked to recall the terms and the category to which they belong. Higher total scores for words recognized on recognition trial indicate better verbal memory.

    Time frame: Day 30, Day 91

  21. Loneliness using the UCLA Loneliness Scale (UCLA)

    The UCLA assesses subjective measures of loneliness and social isolation. Scores range from 0-60 with higher scores indicating more subjective loneliness

    Time frame: Day 30, Day 91

  22. Subjective Perception of pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath using the Edmonton Symptom Assessment System Revised (ESAS-r)

    The ESAS-r assesses 10 common symptoms: pain, tiredness, drowsiness, nausea, lack of appetite, shortness of breath, depression, anxiety, well-being and constipation. It conveys the individual's description of the severity of a symptom based on a scale ranging from 0 to 10. With higher scores indicating higher symptom severity

    Time frame: Day 30, Day 91

  23. Symptoms of PTSD using the PTSD Checklist for DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-administered measure that assesses the 20 DSM-5 symptoms of PTSD. The total scores range from 0-80, with higher scores indicating more symptom severity for PTSD.

    Time frame: Day 30, Day 91

  24. Borderline Personality Disorder Symptoms using the Borderline Symptom List (BSL-23)

    The BSL-23 is a 23-item self-rating instrument for specific assessment of borderline personality disorder (BPD) symptomatology. The average score of items (range 0 to 4, sum of scores divided by 23) is calculated, with a higher score indicating more impairment.

    Time frame: Day 30, Day 91

  25. Sleep Quality using the The Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The global PSQI score ranges from 0-21, with higher scores indicating poorer sleep quality

    Time frame: Day 30, Day 91

  26. Automatic negative self-schema using the Depression Implicit Association Test (Depression IAT)

    The Depression IAT measures the strength of automatic (implicit) associations between concepts (SAD and HAPPY) in people's minds relying on latency measures in a simple sorting task. Scores range from -1 to 1, with positive scores indicating a stronger association between 'ME-SAD' and 'NOT ME-HAPPY' and negative scores indicating a stronger association between 'ME-HAPPY' and 'NOT ME-SAD'.

    Time frame: Day 30, Day 91

  27. Depression Rumination using the The 10-item ruminative response scale (RRS-10)

    Severity of Depression Rumination is measured using the RRS-10. Scores range from 10 to 40, with higher scores indicating more severe depression rumination.

    Time frame: Day 30, Day 91

  28. i-CBT engagement using number of logins per day into i-CBT platform

    Number of logins per day into the i-CBT platform is measured to assess i-CBT engagement.

    Time frame: Weekly up to Day 91.

  29. i-CBT engagement using amount of time logged into the i-CBT platform.

    Amount of time logged in on the i-CBT platform (in minutes) is measured to assess i-CBT engagement.

    Time frame: Weekly up to Day 91.

  30. i-CBT engagement using time spent on each i-CBT module

    Time spent on each i-CBT session is measured to assess i-CBT engagement.

    Time frame: Weekly up to Day 91.

  31. i-CBT engagement

    Number of logins per day, amount of time logged in, time spent on each session, time of day logged in, and time spent in each section of the module of the internet-based CBT will be measured to assess i-CBT engagement.

    Time frame: Weekly up to Day 91.

  32. Addiction Potential Using the Drug Liking and Craving Questionnaire (DLCQ)

    The likeability and craving for the study drug is assessed using the DLCQ. Likeability scores range from 0-10, with higher scores indicating more likeability. How much the participant is craving the study drug is rated on a scale of 0-10, with higher scores indicating more cravings. Craving for using greater amounts ranges from 0 to 10, with higher scores indicating more craving for greater amounts of study drug.

    Time frame: 30 minutes Post Infusion, at Day 30, weekly after Day 30 up to Day 91.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 38 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 38 months is close to that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Mar 2026 → Mar 2027 and completion Jun 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2022
First posted
Jun 28, 2024
StartActual
Jan 2, 2024
Primary completionEst.
Mar 31, 2027was Mar 2026
CompletionEst.
Mar 31, 2027was Jun 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Primary completion
Mar 2026→Mar 31, 2027
Oct 6, 2026
Study completion
Jun 2026→Mar 31, 2027
Oct 6, 2026
Enrollment
110→76
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 2026→Mar 31, 2027
    Study completion Jun 2026→Mar 31, 2027
    Enrollment 110→76
    + 4 other changes: description, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06480500
Collaborators
Ontario Shores Centre for Mental Health Sciences
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Jan 2, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Rodrigo Mansur
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion